# EDGAR Filing Document

**Accession Number:** 0001851194
**File Stem:** 0001874108-26-000002
**Filing Date:** 2026-3
**Character Count:** 8966
**Document Hash:** a0ecba277b13b487fa87309340822251
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001874108-26-000002.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001874108-26-000002

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260304

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Nuss John
- **CENTRAL INDEX KEY:** 0001874108

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40928
- **FILM NUMBER:** 26721588

**MAIL ADDRESS:**
- **STREET 1:** C/O VENTYX BIOSCIENCES, INC.
- **STREET 2:** 12790 EL CAMINO REAL, SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ventyx Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001851194
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832996852
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 12790 EL CAMINO REAL, SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 7604076511

**MAIL ADDRESS:**
- **STREET 1:** 12790 EL CAMINO REAL, SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Nuss John<br><sub>(Last) (First) (Middle)</sub><br>C/O VENTYX BIOSCIENCES, INC.<br>12790 EL CAMINO REAL, SUITE 200<br><sub>(Street)</sub><br>SAN DIEGO, CA 92130<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CHIEF SCIENTIFIC OFFICER_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Ventyx Biosciences, Inc. [ VTYX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-03-04 |  | D<sup>(1)</sup> |  | 489481 | D | <sup>(2)</sup> | 0 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(3)</sup> | 2026-03-04 |  | D<sup>(1)</sup> |  |  | 9063 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 9063 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (right to buy) | $2.14 | 2026-03-04 |  | D<sup>(1)</sup> |  |  | 415104 | <sup>(4)</sup> | 2035-01-02 | Common Stock | 415104 | <sup>(4)</sup> | 0 | D |  |
| Stock Option (right to buy) | $2.49 | 2026-03-04 |  | D<sup>(1)</sup> |  |  | 125000 | <sup>(4)</sup> | 2034-01-02 | Common Stock | 125000 | <sup>(4)</sup> | 0 | D |  |
| Stock Option (right to buy) | $2.14 | 2026-03-04 |  | D<sup>(1)</sup> |  |  | 181250 | <sup>(4)</sup> | 2033-12-18 | Common Stock | 181250 | <sup>(4)</sup> | 0 | D |  |
| Stock Option (right to buy) | $8.04 | 2026-03-04 |  | D<sup>(1)</sup> |  |  | 192778 | <sup>(4)</sup> | 2031-09-18 | Common Stock | 192778 | <sup>(4)</sup> | 0 | D |  |
| Stock Option (right to buy) | $14.48 | 2026-03-04 |  | D<sup>(1)</sup> |  |  | 145000 | <sup>(5)</sup> | 2032-02-04 | Common Stock | 145000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option (right to buy) | $14.48 | 2026-03-04 |  | D<sup>(1)</sup> |  |  | 139722 | <sup>(5)</sup> | 2031-12-17 | Common Stock | 139722 | <sup>(5)</sup> | 0 | D |  |
| Stock Option (right to buy) | $33.84 | 2026-03-04 |  | D<sup>(1)</sup> |  |  | 108750 | <sup>(5)</sup> | 2033-01-17 | Common Stock | 108750 | <sup>(5)</sup> | 0 | D |  |

---

### Footnotes:

(1) Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent.

(2) At the effective time of the Merger (the "Effective Time"), these shares were automatically converted solely into the right to receive cash in an amount equal to $14.00 (without interest) per share (the "Per Share Price"), subject to the terms and conditions of the Merger Agreement.

(3) At the Effective Time, each outstanding restricted stock unit ("RSU") that was unvested was cancelled and converted solely into the right to receive a cash award (without interest) equal to (i) the total number of shares of common stock subject to such unvested RSU award immediately prior to the Effective Time, multiplied by (ii) the Per Share Price, less applicable withholding taxes.

(4) At the Effective Time, this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.

(5) At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration.

**Signature:** /s/ Austin Rutherford, as Attorney-in-Fact  
**Date:** 2026-03-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**